XTRA:ACTChemicals
AlzChem Group (XTRA:ACT) Could Be 25% Undervalued As Strong 2026 Earnings Land
AlzChem Group (XTRA:ACT) has drawn fresh attention after reporting second quarter and first half 2026 results, with both sales and net income higher than the same periods a year earlier.
See our latest analysis for AlzChem Group.
Despite the stronger first half of 2026 results, AlzChem Group’s share price has fallen 11.6% over the past day and is down 12.3% over the past week, although the 5 year total shareholder return of over 6x points to a much stronger longer term picture.
If this...